Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

There is growing evidence that the body’s energy expenditures constitute a significant risk factor for the development of most deadly diseases, including cancer. Our aim was to investigate the impact of basal metabolic rate (BMR) on the growth and progression of colorectal cancer (CRC). To do so, we used a unique model consisting of three lines of laboratory mice (Mus musculus) artificially selected for high (HBMR) and low (LBMR) basal metabolic rate and randomly bred individuals (non-selected, NSBMR). The experimental individuals were implanted with human colorectal cancer cells DLD-1. The variation in BMR between the lines allowed for testing the impact of whole-body metabolism on oxidative and antioxidant parameters in the liver throughout the cancerogenesis process. We investigated the dependence between metabolic values, reactive oxygen species (ROS) levels, and Kelch-like ECH-associated protein 1-based E3 ligase complexes (Keap1) gene activity in these animals. We found that the HBMR strain had a higher concentration of oxidative enzymes compared to the LBMR and NSBMR. Furthermore, the growth rate of CRC tumors was associated with alterations in the levels of oxidative stress enzymes and Keap1 expression in animals with a high metabolic rate. Our results indicate that a faster growth and development of CRC line DLD-1 is associated with enzymatic redox imbalance in animals with a high BMR.

Details

Title
Metabolic Rate and Oxidative Stress as a Risk Factors in the Development of Colorectal Cancer
Author
Sawicka, Diana 1   VIAFID ORCID Logo  ; Maciak, Sebastian 2   VIAFID ORCID Logo  ; Sadowska, Anna 1   VIAFID ORCID Logo  ; Sokołowska, Emilia 3   VIAFID ORCID Logo  ; Gohal, Sylwia 1 ; Guzińska-Ustymowicz, Katarzyna 4 ; Niemirowicz-Laskowska, Katarzyna 1 ; Car, Halina 1   VIAFID ORCID Logo 

 Department of Experimental Pharmacology, Medical University of Bialystok, Szpitalna Street 37, 15-295 Bialystok, Poland; [email protected] (A.S.); [email protected] (S.G.); [email protected] (K.N.-L.); [email protected] (H.C.) 
 Department of Evolutionary and Physiological Ecology, Faculty of Biology, University of Bialystok, Ciolkowskiego Street 1J, 15-245 Bialystok, Poland; [email protected] 
 Department of Clinical Pharmacology, Medical University of Bialystok, Waszyngtona Street 15A, 15-274 Bialystok, Poland; [email protected] 
 Department of General Pathomorphology, Medical University of Bialystok, Waszyngtona Street 13, 15-269 Bialystok, Poland; [email protected] 
First page
10713
Publication year
2024
Publication date
2024
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3116670877
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.